Anti-Human Frizzled receptor Recombinant Antibody (Vantictumab)

Customer Review

There are currently no Customer reviews or questions for TAB-880. Click the button above to contact us or submit your feedback about this product.

Citations

1. Nanki, Kosaku, et al. "Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis." Cell 174.4 (2018): 856-869. https://doi.org/10.1016/j.jmva.2018.03.007
   This study established and characterized a collection of 37 patient-derived gastric cancer (GC) organoids representing diverse histological and molecular subtypes of clinical GCs. The research revealed how genetic and epigenetic alterations affect niche factor dependencies in GC organoids. Through phenotype-genotype correlation analyses, the researchers identified that CDH1/TP53 compound mutations confer R-spondin independency, while RNF43/ZNRF3 gene alterations and epigenetic modifications contribute to Wnt niche independency. Using CRISPR-Cas9 gene editing in normal gastric organoids, they validated these findings and demonstrated that disruption of adherens junctions plays a critical role in diffuse-type GC morphological transformation. Xenograft studies further established the potential of Wnt-targeting therapy for a subset of Wnt-dependent GCs.
   Creative Biolabs provided the human monoclonal anti-human Frizzled receptor antibody (OMP-18R5, CAT# TAB-880) that was instrumental in the flow cytometry analysis of Frizzled receptor expression on GC organoid surfaces. This antibody helped the researchers determine that CT mutant GC organoids gained R-spondin independency through a mechanism distinct from RNF43/ZNRF3 mutations by allowing them to assess Frizzled receptor expression levels with and without R-spondin stimulation, thus clarifying how different genetic alterations impact the Wnt signaling pathway in gastric cancer development.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-880, RRID: AB_3112013)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Nanki, Kosaku, et al. "Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis." Cell 174.4 (2018): 856-869.

Biosimilar Overview

Please refer to Vantictumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Vantictumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Vantictumab"

Afuco™ Anti-Frizzled Receptor ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-880)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human Frizzled receptor. It is a monoclonal antibody designed for the treatment of cancer.

DrugMonitor™ Anti-Vantictumab Antibody (VS-1224-YC1274)

Vantictumab has been used in trials for treating solid tumors and pancreatic cancer, including stage IV pancreatic cancer. The DrugMonitor™ Anti-Vantictumab Antibody (VS-1224-YC1274) is an anti-drug antibody (ADA) against Vantictumab. This drug-based antibody is raised in mice immunized with the Vantictumab. The anti-Vantictumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Vantictumab in samples.

See other products for "Frizzled receptor"

Select a product category from the dropdown menu below to view related products.